MedPath

江苏海岸药业有限公司

Ownership
-
Established
2012-05-14
Employees
-
Market Cap
-
Website
http://www.haianyaoye.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

20

NMPA:20

Drug Approvals

Empagliflozin Tablets

Product Name
恩格列净片
Approval Number
国药准字H20258032
Approval Date
Mar 19, 2025
NMPA

Posaconazole Enteric-coated Tablets

Product Name
泊沙康唑肠溶片
Approval Number
国药准字H20243033
Approval Date
Jan 9, 2024
NMPA

Phloroglucinol Injection

Product Name
间苯三酚注射液
Approval Number
国药准字H20234732
Approval Date
Dec 29, 2023
NMPA

Aprepitant Capsules

Product Name
阿瑞匹坦胶囊
Approval Number
国药准字H20233866
Approval Date
Jun 30, 2023
NMPA

Aprepitant Capsules

Product Name
阿瑞匹坦胶囊
Approval Number
国药准字H20233867
Approval Date
Jun 30, 2023
NMPA

Empagliflozin Tablets

Product Name
恩格列净片
Approval Number
国药准字H20233742
Approval Date
Jun 21, 2023
NMPA

Lacosamide Injection

Product Name
拉考沙胺注射液
Approval Number
国药准字H20223813
Approval Date
Nov 8, 2022
NMPA

Sugammadex Sodium Injection

Product Name
舒更葡糖钠注射液
Approval Number
国药准字H20223225
Approval Date
Apr 12, 2022
NMPA

Sugammadex Sodium Injection

Product Name
舒更葡糖钠注射液
Approval Number
国药准字H20223224
Approval Date
Apr 12, 2022
NMPA

Ambroxol Hydrochloride Injection

Product Name
盐酸氨溴索注射液
Approval Number
国药准字H20213353
Approval Date
May 11, 2021
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.